Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2021 Apr;82(4):84-123.
doi: 10.1016/j.jinf.2020.11.016. Epub 2020 Nov 17.

Outcome prediction by serum calprotectin in patients with COVID-19 in the emergency department

Wolfgang Bauer  1 , Eva Diehl-Wiesenecker  2 , Jannis Ulke  3 , Noa Galtung  2 , Aleksandra Havelka  4 , J Kolja Hegel  5 , Rudolf Tauber  6 , Rajan Somasundaram  2 , Kai Kappert  6
Affiliations
Comment

Outcome prediction by serum calprotectin in patients with COVID-19 in the emergency department

Wolfgang Bauer et al. J Infect. 2021 Apr.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Declaration of Competing Interest This study was financially supported by Gentian AS.

Figures

Fig. 1
Fig. 1
(A) Patient enrollment and outcomes and (B) receiver operating characteristics with scatterplots for calprotectin predicting those outcomes. The scatterplots include a broken y axis. The horizontal bar on the scatterplot represents the median calprotectin concentration. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
See this image and copyright information in PMC

Comment on

References

    1. Luis Garcia de Guadiana R., Mulero M.D.R., Olivo M.H., Rojas C.R., Arenas V.R., Morales M.G., Abellan A.B., Conesa-Zamora P., Garcia-Garcia J., Hernandez A.C., Morell-Garcia D., Dolores Albaladejo-Oton M., Consuegra-Sanchez L. Circulating levels of GDF-15 and calprotectin for prediction of in-hospital mortality in COVID-19 patients: a case series. J Infect. 2020 - PMC - PubMed
    1. Skevaki C., Fragkou P.C., Cheng C., Xie M., Renz H. Laboratory characteristics of patients infected with the novel SARS-CoV-2 virus. J Infect. 2020;81:205–212. - PMC - PubMed
    1. Silvin A., Chapuis N., Dunsmore G., Goubet A.G., Dubuisson A., Derosa L., Almire C., Henon C., Kosmider O., Droin N., Rameau P., Catelain C., Alfaro A., Dussiau C., Friedrich C., Sourdeau E., Marin N., Szwebel T.A., Cantin D., Mouthon L., Borderie D., Deloger M., Bredel D., Mouraud S., Drubay D., Andrieu M., Lhonneur A.S., Saada V., Stoclin A., Willekens C., Pommeret F., Griscelli F., Ng L.G., Zhang Z., Bost P., Amit I., Barlesi F., Marabelle A., Pene F., Gachot B., Andre F., Zitvogel L., Ginhoux F., Fontenay M., Solary E. Elevated calprotectin and abnormal myeloid cell subsets discriminate severe from mild COVID-19. Cell. 2020;182:1401–1418. e18. - PMC - PubMed
    1. Shi H., Zuo Y., Yalavarthi S., Gockman K., Zuo M., Madison J.A., Blair C.N., Woodard W., Lezak S.P., Lugogo N.L., Woods R.J., Lood C., Knight J.S., Kanthi Y. Neutrophil calprotectin identifies severe pulmonary disease in COVID-19. medRxiv. 2020 - PMC - PubMed
    1. Chen L., Long X., Xu Q., Tan J., Wang G., Cao Y., Wei J., Luo H., Zhu H., Huang L., Meng F., Huang L., Wang N., Zhou X., Zhao L., Chen X., Mao Z., Chen C., Li Z., Sun Z., Zhao J., Wang D., Huang G., Wang W., Zhou J. Elevated serum levels of S100A8/A9 and HMGB1 at hospital admission are correlated with inferior clinical outcomes in COVID-19 patients. Cell Mol Immunol. 2020;17:992–994. - PMC - PubMed

Substances